Azithromycin for improving pulmonary function in cystic fibrosis

被引:10
作者
Carr, RR
Nahata, MC
机构
[1] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH 43210 USA
[3] Childrens Hosp, Columbus, OH 43205 USA
关键词
adults; azithromycin; children; cystic fibrosis;
D O I
10.1345/aph.1D589
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review the literature concerning the use of azithromycin in the treatment of patients with cystic fibrosis (CF). DATA SOURCES: A search of MEDLINE (1966-April 2004), Embase (1980-April 2004), and International Pharmaceutical Abstracts (1971-April 2004) was performed. Search terms included cystic fibrosis, macrolide, and azithromycin. DATA SYNTHESIS: Four studies have been performed in 7-185 patients (children and adults) over a 3- to 6-month period. The azithromycin dosage ranged from 250 mg 3 times weekly to 500 mg daily. The trials reported an improvement in percent predicted forced expiratory volume ranging from 2.95% to 6.2% in patients treated with azithromycin compared with those receiving placebo. CONCLUSIONS: Azithromycin appeared to improve pulmonary function in adults and older children with CF and was well tolerated when administered for 6 months. Further research is needed to determine an optimal dosage regimen, duration of treatment, effects on quality of life, and cost-effectiveness of azithromycin therapy.
引用
收藏
页码:1520 / 1524
页数:5
相关论文
共 15 条
  • [1] [Anonymous], 2000, ADV DATA, V314, P1, DOI DOI 10.1186/1475-2875-6-146
  • [2] Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial
    Equi, A
    Balfour-Lynn, IM
    Bush, A
    Rosenthal, M
    [J]. LANCET, 2002, 360 (9338) : 978 - 984
  • [3] MUCOID PSEUDOMONAS-AERUGINOSA IS A MARKER OF POOR SURVIVAL IN CYSTIC-FIBROSIS
    HENRY, RL
    MELLIS, CM
    PETROVIC, L
    [J]. PEDIATRIC PULMONOLOGY, 1992, 12 (03) : 158 - 161
  • [4] Long-term azithromycin may improve lung function in children with cystic fibrosis
    Jaffé, A
    Francis, J
    Rosenthal, M
    Bush, A
    [J]. LANCET, 1998, 351 (9100) : 420 - 420
  • [5] A MECHANISM OF ERYTHROMYCIN TREATMENT IN PATIENTS WITH DIFFUSE PANBRONCHIOLITIS
    KADOTA, J
    SAKITO, O
    KOHNO, S
    SAWA, H
    MUKAE, H
    ODA, H
    KAWAKAMI, K
    FUKUSHIMA, K
    HIRATANI, K
    HARA, K
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (01): : 153 - 159
  • [6] Kobayashi H., 1995, AM J MED, V99, P26
  • [7] Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children
    Kogan, R
    Martínez, MA
    Rubilar, L
    Payá, E
    Quevedo, I
    Puppo, H
    Girardi, G
    Castro-Rodriguez, JA
    [J]. PEDIATRIC PULMONOLOGY, 2003, 35 (02) : 91 - 98
  • [8] Lai HC, 1999, AM J CLIN NUTR, V69, P531
  • [9] LONG-TERM LOW-DOSE ADMINISTRATION OF ERYTHROMYCIN TO PATIENTS WITH DIFFUSE PANBRONCHIOLITIS
    NAGAI, H
    SHISHIDO, H
    YONEDA, R
    YAMAGUCHI, E
    TAMURA, A
    KURASHIMA, A
    [J]. RESPIRATION, 1991, 58 (3-4) : 145 - 149
  • [10] Cystic fibrosis
    Ratjen, F
    Döring, G
    [J]. LANCET, 2003, 361 (9358) : 681 - 689